Drugs / CTX-471
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03881488 | May 2019 → May 2025 | head and neck cancer, melanoma, mesothelioma, metastatic malignant neoplasm +2 | Compass Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07392957 | Jun 2026 → Jun 2029 expected | glioblastoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07684170 | Sep 2026 → Sep 2028 expected | neuroendocrine carcinoma | Compass Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX-471 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03881488 ↗ |
| Action | Restore | “CTX-471 restores local immune reactivity through activation of costimulatory immune mediators” NCT07392957 ↗ |
| Route | Intravenous | “IV infusion every 2 weeks” NCT03881488 ↗ |